A recent study has found that in type 2 diabetes patients hospitalized with COVID-19, those who had Sitagliptin added to the standard care of diabetes treatment (insulin administration), the mortality rate was lowered (18% vs. 37% of deceased patients)54. This evidence concerns the gene INS and type 2 diabetes mellitus.